A Phase II Study of the Clinical and Immunological Effects of NY-ESO-1 ISCOM Vaccine in Patients With Measurable Stage III and IV Malignant Melanoma.

Trial Profile

A Phase II Study of the Clinical and Immunological Effects of NY-ESO-1 ISCOM Vaccine in Patients With Measurable Stage III and IV Malignant Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs NY-ESO-1 ISCOMATRIX (Primary) ; Cyclophosphamide
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Oct 2009 Planned end date changed from 1 Apr 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.
    • 21 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top